ClinicalTrials.gg

Drug

Gemfibrozil clinical trials

Also written Lopid and PLX-200.

studies test it
28
open now
1
in phase 3
2
first study started
1991

Keep track of what changes. Save the Gemfibrozil studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Brand

Development codes

Combined with it in one product

Studies by the year they started

27 studies that test it; most in 2012 (3); 1 more planned to start later

Studies that test Gemfibrozil, by start year
YearStudies
19911
20041
20051
20071
20091
20102
20111
20123
20131
20143
20151
20161
20181
20201
20212
20232
20241
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
20
Phase 2
5
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it.

Who runs them

Industry 22 · Other 6

Bristol-Myers Squibb (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Astellas Pharma Europe B.V. (2) · Polaryx Therapeutics, Inc. (2) · Hoffmann-La Roche (1) · Sanofi (1) · Bellus Health Inc. - a GSK company (1)

Often tested with

Tested in the same studies.

Itraconazole (7) · Rifampin (3) · Ketoconazole (2) · Cyclosporine (1) · BLU-5937 (1) · Dabigatran (1) · Selexipag (1) · VX-993 (1)

Studies

Open first, then newest update. How each study uses Gemfibrozil is read from its arms, and is right about nine times in ten.

Testing it · 28

See all 28 studies that test Gemfibrozil →

As the comparator · 1 — what is tested is compared with Gemfibrozil

Codes

What other systems call Gemfibrozil · ClinicalTrials.gg INT008450

  • MeSH (NLM) D015248GemfibrozilConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) Q8X02027X3GEMFIBROZILConfirmed FDA, NLM, Wikidata
  • RxNorm 4719Confirmed FDA, Wikidata
  • Wikidata Q384295gemfibrozilConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C29071GemfibrozilOne source FDA
  • DrugBank DB01241One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.